In addition, a recent study has explored the efficacy and safety of the combination of anti-CD19 and anti-BCMA CAR-T cell therapy in 10 newly diagnosed MM patients with high-risk factors, and all patients achieved a clinical response (32). Here, CD19 is linked to Miyoshi myopathy.